ClinicalTrials.gg
CompletedNCT07071558Updated Apr 28, 2026

Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

A Phase 1 interventional study of RSV vaccine formulation 1 dose and RSV vaccine formulation 2 dose in Respiratory Syncytial Virus Immunization, sponsored by Sanofi. Completed at 6 sites in Australia. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Sanofi · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies in Respiratory Syncytial Virus Infections by Sanofi — none open to participants now, 2 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Sanofi.

Enrollment
9th of 14
240 · median 310
Started
2025
the only one that year
Phase 1
8 of 15
none open now
Registered
14th of 15
by date

Among the 15 studies in Respiratory Syncytial Virus Infections by Sanofi, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 1, and was the 14th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 15 studies in Respiratory Syncytial Virus Infections by Sanofi is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Respiratory Syncytial Virus Infections by Sanofi as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of different liponanaoparticle (LNP) formulations of modified ribonucleic acid (mRNA) vaccines using the RSV pre-F antigen in healthy participants 18 to 49 years of age.

-Each participant will remain in the study for approximately 6 months.

  • The study intervention will be administered as a single intramuscular (IM) dose in the upper arm on Day 1 (D01).
  • The visit frequency will include 1 Screening Visit, 4 planned site visits to occur on D01, D03, D08, and D29, and 2 telephone calls to occur at Month (M)3 and M6.
03

Conditions studied

  • Respiratory Syncytial Virus Immunization

Keywords

  • RSV
  • RSV Infection
  • RSV Vaccine
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 49 years on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and of the following conditions applies:

    • Is of NCBP (Non-). To be considered of NCBP, a female must be for at least 1 year, or surgically sterile. OR
    • Is of CBP (Child-Bearing Potential) and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

Exclusion criteria

Exclusion Criteria:

  • Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    RSV Formulation 1

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 1 dose

  • Experimental
    RSV Formulation 2

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 2 dose

  • Experimental
    RSV Formulation 3

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 3 dose

  • Experimental
    RSV Formulation 4

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 4 dose

  • Experimental
    RSV Formulation 5

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 5 dose

  • Experimental
    RSV Formulation 6

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 6 dose

  • Experimental
    Control group 1 dose 1

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 7 dose

  • Experimental
    Control group 2 dose 2

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV vaccine formulation 8 dose

Interventions

  • BiologicalRSV vaccine formulation 1 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 2 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 3 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 4 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 5 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 6 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 7 dose

    Suspension for injection. Route of administration: IM injection

  • BiologicalRSV vaccine formulation 8 dose

    Suspension for injection. Route of administration: IM injection

06

What researchers measure

Primary outcomes

  1. Presence of any unsolicited systemic adverse events (aes)

    Number of participants experiencing immediate AEs

    Time frame: Within 30 minutes after each vaccine injection

  2. Presence of solicited injection site reactions (ie, pre-listed in the participant's diary and in the eCRF (electronic case report form)

    Number of participants experiencing solicited injection site reactions

    Time frame: Through 7 days after each vaccine injection

  3. Presence of solicited systemic reactions (ie, pre-listed in the participant diary and in the CRF)

    Number of participants experiencing solicited systemic reactions

    Time frame: Through 7 days after each vaccine injection

  4. Presence of unsolicited AEs

    Number of participants experiencing unsolicited AEs

    Time frame: Day 1 through day 29

  5. Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Events of Special Interest)

    Number of participants experiencing SAEs and AESIs

    Time frame: Throughout study, approximately 6 months

  6. Presence of out-of-range biological test results (including shift from baseline values)

    number of participants with out-of-range biological tests

    Time frame: Through 7 days after each vaccine injection

  7. RSV A nAb (Neutralizing Antibodies) titers

    Time frame: At day 1 and day 29

07

Study locations

6 sites
  • Site # 0361003
    Wollongong, New South Wales 2500, Australia
  • Site # 0361006
    Brisbane, Queensland 4006, Australia
  • Site # 0361005
    Morayfield, Queensland 4506, Australia
  • Site # 0361004
    Southport, Queensland 4215, Australia
  • Site # 0361002
    Bayswater, Victoria 3153, Australia
  • Site # 0361001
    Camberwell, Victoria 3124, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Mar 2026, 8 months.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 8 months is above that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartActual
Jul 14, 2025
Primary completionActual
Mar 17, 2026
CompletionActual
Mar 17, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071558
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Jul 14, 2025
Primary completion
Mar 17, 2026
Completion
Mar 17, 2026
Last update
Apr 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion